Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. (ENTA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ENTA · as of Sep 30, 2025
Ownership Breakdown
127
Institutional Holders
▲ 19 vs Q2
$227.12M
Total Inst. Value
▲ $87.69M vs Q2
23.22M
Shares Outstanding
freeFloat 87.00%
18.99M
13F Shares Held
▲ 548,752 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ENTA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FARALLON CAPITAL MANAGEMENT LLC pharmaceutical preparations | 2.12M | 9.95% | 9.95% | $25.40B | Feb 17, 2026 | — held |
KRENSAVAGE ASSET MANAGEMENT, LLC pharmaceutical preparations | 2.11M | 9.92% | 9.92% | $25.31B | Nov 17, 2025 | — held |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 1.95M | 9.13% | 9.13% | $23.29B | Nov 14, 2025 | ▲ 1.42M |
VANGUARD GROUP INC pharmaceutical preparations | 1.94M | 9.09% | 9.09% | $23.21B | Nov 7, 2025 | ▼ 37.8K |
BLACKROCK, INC. pharmaceutical preparations | 1.83M | 8.60% | 8.60% | $21.94B | Nov 12, 2025 | ▼ 13.9K |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 948.1K | 4.45% | 4.45% | $11.35B | Nov 14, 2025 | ▼ 510.5K |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 867.0K | 4.07% | 4.07% | $10.37B | Nov 13, 2025 | — held |
COMMODORE CAPITAL LP pharmaceutical preparations | 800.0K | 3.75% | 3.75% | $9.58B | Nov 14, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 493.2K | 2.31% | 2.31% | $5.90B | Nov 12, 2025 | ▲ 7.4K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 479.6K | 2.25% | 2.25% | $5.74B | Nov 13, 2025 | ▲ 10.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
15
Increased
+1.92M shares7
New Positions
first time holders21
Decreased
−2.05M shares0
Sold Out
fully exitedNet shares change (top 50)
128.2K
+1.92M / −2.05M
Net new holders
+1
7 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ENTA insider trading · insider activity
Source: SEC Form 4
18
Buy transactions
6
Sell transactions
3.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Vance Terry director | Mar 11, 2026 | Award | 20,000 | $14.17 | $283.4K | 20.0K | Form 4 ↗ |
Russell Lesley director | Mar 11, 2026 | Award | 20,000 | $14.17 | $283.4K | 20.0K | Form 4 ↗ |
Peterson Kristine director | Mar 11, 2026 | Award | 20,000 | $14.17 | $283.4K | 20.0K | Form 4 ↗ |
Hata Yujiro S director | Mar 11, 2026 | Award | 20,000 | $14.17 | $283.4K | 20.0K | Form 4 ↗ |
FOLETTA MARK G director | Mar 11, 2026 | Award | 20,000 | $14.17 | $283.4K | 20.0K | Form 4 ↗ |
CARTER BRUCE L A director | Mar 11, 2026 | Award | 20,000 | $14.17 | $283.4K | 20.0K | Form 4 ↗ |
Kowalsky Matthew Paul Chief Legal Officer | Feb 12, 2026 | Award | 4,175 | — | — | 5.5K | Form 4 ↗ |
Kowalsky Matthew Paul Chief Legal Officer | Feb 12, 2026 | Tax Withhold | 1,902 | $14.25 | $27.1K | 3.6K | Form 4 ↗ |
Kowalsky Matthew Paul Chief Legal Officer | Feb 12, 2026 | Award | 1,318 | — | — | 1.3K | Form 4 ↗ |
Luu Brendan Chief Business Officer | Feb 12, 2026 | Award | 4,987 | — | — | 44.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Enanta Pharmaceuticals, Inc. (ENTA) is primarily owned by institutional investors, who hold approximately 81.8% of total shares outstanding. Company insiders own approximately 13.00%, while retail and public investors account for the remaining 5.20%.
The largest institutional shareholder of Enanta Pharmaceuticals, Inc. is FARALLON CAPITAL MANAGEMENT LLC, holding approximately 2.12 million shares — equal to 9.95% of outstanding shares — as of September 30, 2025.
A total of 127 institutional investors currently hold ENTA stock, with a combined institutional value of approximately $227,117,807 as of the most recent 13F filing period.
Frequently asked questions
ENTA ownershipEnanta Pharmaceuticals, Inc. (ENTA) is primarily owned by institutional investors, who hold approximately 81.8% of shares. The largest shareholder is FARALLON CAPITAL MANAGEMENT LLC with a 9.95% stake. Company insiders hold 13.00%. Data sourced from SEC Form 13F as of September 30, 2025.